Maexeni

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maexeni

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablets (Film-coated, Monophasic)
Pharmacological Class Combined Oral Contraceptive (COC)
General Purpose Pregnancy Prevention
Origin Synthetic Hormones

What Type of Medicine is Maexeni?

Maexeni is a prescription-only medicine (Rx) that belongs to the pharmacological class of Hormonal Contraceptives, specifically identified as a Combined Oral Contraceptive (COC). This designation confirms the medication's composition as a combination of two types of synthetic sex hormones, supplied as oral tablets for consistent, daily administration. Combination products containing Ethinyl Estradiol and Levonorgestrel are a well-recognized standard method for contraception.

What is the Composition of Maexeni?

The identity of Maexeni is defined by its composition as a combination product of two distinct synthetic hormones: Ethinyl Estradiol (a synthetic estrogen) and Levonorgestrel (a synthetic progestin). This product is manufactured as a monophasic formulation, ensuring the dose of both active components remains fixed in every tablet of the active cycle.

What is the General Purpose of Maexeni?

The principal function of Maexeni is highly effective pregnancy prevention, serving as a reliable form of contraception for women of childbearing potential. This therapeutic benefit is achieved through the systemic delivery of the sex hormone combination, which is clinically recognized for its ability to regulate the female reproductive cycle.

What side effects are possible with Maexeni?

Possible Side Effects and Safety Information

This section details the officially documented adverse effects and safety characteristics of Maexeni (Ethinyl Estradiol/Levonorgestrel), as compiled from government regulatory sources (e.g., FDA, EMA Summary of Product Characteristics).


Official Adverse Reactions by Frequency

Adverse reactions are classified by frequency as documented in regulatory clinical data:

Frequency Classification Common Adverse Reactions System-Organ Classes
Very Common (ge 1/10) Headache, Nausea, Irregular Uterine Bleeding Nervous System, Gastrointestinal, Reproductive System
Common (ge 1/100 to < 1/10) Migraine, Weight Increased, Breast Tenderness, Depressed Mood, Acne Nervous System, Metabolism, Reproductive System, Psychiatric
Rare (< 1/1,000) Venous Thromboembolism (VTE), Arterial Thromboembolism (ATE) Vascular Disorders

Serious Safety Risks and Contraindications

The official safety profile highlights the rare but serious risk of Thromboembolic Events, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction. Other serious documented risks include Hepatic Neoplasia (liver tumors) and new onset or worsening Hypertension.

Population-Specific Safety Constraints

Regulatory documentation specifies several critical constraints:

  • Absolute Contraindication: The medication is contraindicated for smokers aged 35 or older due to the significantly increased risk of serious cardiovascular events.
  • Contraindication: Use is restricted for women with a history of migraines with aura.
  • Peri-Surgical/Immobilization: The product must be discontinued at least four weeks before and for two weeks after major surgery or any period of prolonged immobilization, due to heightened VTE risk.

Time-Related Risk Patterns

Regulatory documents state that the risk of Venous Thromboembolism (VTE) is explicitly highest during the first year of use and when restarting the medicine after a break of four weeks or more.

Overdose and Emergency Response

Maexeni Overdose and when to seek help

The official regulatory profile for acute overdose of combined oral contraceptives (Maexeni: Ethinyl Estradiol / Levonorgestrel) indicates that ingestion of large quantities is generally not likely to be life-threatening. Despite this low acute toxicity classification, certain clinical signs and manifestations are officially documented and require immediate attention.

Documented Overdose Manifestations

Symptoms documented in the regulatory prescribing information primarily involve the gastrointestinal and reproductive systems. These typically include nausea and vomiting. A common hormonal-related sign is vaginal bleeding (withdrawal bleeding), which may present as spotting or heavy breakthrough bleeding. This specific manifestation has been reported to occur in females, including those who are prepubertal, after consuming an overdose.

Required Emergency Action

Immediate professional consultation is required in all suspected overdose situations. Regulators mandate that individuals must seek medical help right away by contacting emergency services or a Poison Control Center for immediate professional assessment and management. Treatment for Maexeni overdose is mandated to be symptomatic and supportive, focusing on managing the reported clinical signs. Medical professionals may utilize procedures like activated charcoal to limit drug absorption, and continuous monitoring of vital signs may be required. Officially, no specific antidote is known for combined oral contraceptive overdose.

Therapeutic Uses of Maexeni

What Maexeni Treats: Main Uses and Benefits

The core therapeutic benefits of Maexeni (Ethinyl Estradiol/Levonorgestrel) are applied across domains where additional symptomatic support is needed. This medication is commonly used for a range of cyclical and hormonal symptoms.

Its primary therapeutic domain is reliable support for pregnancy prevention for women of childbearing potential. Additionally, Maexeni is commonly used to help with symptom clusters that may become intense or disruptive, including severe menstrual pain (dysmenorrhea), excessive blood loss (menorrhagia), and hormonal manifestations like moderate to severe acne vulgaris.

Quick Fact: Supportive Management for Symptoms of Cyclical Discomfort

The medication is relevant for easing recurrent symptoms associated with conditions where functional stability becomes affected. This application provides supportive relief that helps patients cope more steadily with difficult episodes, contributing to easing the impact on routine activities and general comfort.

Furthermore, Maexeni is applied across domains where additional symptomatic support is needed by assisting in the management of cycle predictability and regularity and easing the recurrent symptomatic burden associated with severe Premenstrual Dysphoric Disorder (PMDD). This support assists with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Maexeni (Ethinylestradiol / Levonorgestrel) is indicated for use by females of reproductive potential to prevent pregnancy, provided they do not have specific health conditions that significantly increase safety risks.

Contraindicated Populations (Must Not Use)

Official regulatory documents establish absolute contraindications for individuals with conditions that increase the risk of serious cardiovascular events, particularly blood clots (thromboembolism) or hormone-sensitive cancers. Use is strictly prohibited for females who have:

  • A current or history of arterial or venous thrombotic diseases (e.g., Deep Vein Thrombosis, Pulmonary Embolism, stroke, heart attack).
  • Specific risk factors for these diseases, such as smoking if over age 35, uncontrolled hypertension, or diabetes with vascular complications.
  • Current or history of breast cancer or other hormone-sensitive cancers.
  • Liver tumors, severe liver disease, or acute viral hepatitis.
  • Undiagnosed abnormal uterine bleeding.
  • Known or suspected pregnancy.

Restricted or Conditional Use

  • Age: The medicine is not indicated for use before menarche. It is contraindicated in women over 35 who smoke.
  • Postpartum/Lactation: Use is generally not recommended in the immediate postpartum period due to increased thromboembolism risk. It is also not recommended for use in breastfeeding women, as it may decrease milk production.
  • Surgery: Must be discontinued at least four weeks before and for two weeks after major surgery associated with prolonged immobilization.

What should I know about interactions with other medicines?

The official regulatory documents for Maexeni define a structure of pharmacokinetic interactions and specific co-administration restrictions that impact hormone exposure and effectiveness.

Interaction Classification Interacting Substances/Products Regulatory Statement Highlights
Contraindicated Combinations Specific regimens for Hepatitis C Virus (HCV), including products containing Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir. Co-administration is formally prohibited due to the risk of significant liver enzyme elevations.
Reduced Exposure/Efficacy Enzyme Inducers (e.g., Carbamazepine, Rifampicin), St John's wort, and Colesevelam. These substances increase the hormonal clearance via metabolic pathways, potentially diminishing the contraceptive effect.
Altered Exposure of Other Drugs Lamotrigine, Cyclosporine, and Thyroid/Corticosteroid replacement hormones. Maexeni increases the clearance of Lamotrigine, leading to reduced plasma concentrations. It may increase the levels of Cyclosporine and affect replacement hormone requirements.

Population-Specific Restrictions: Use of Maexeni is formally contraindicated in females over 35 years of age who smoke due to the significantly increased risk of serious cardiovascular events. It is also restricted in individuals with severe hepatic disease due to impaired hormone metabolism.

Timing-Based Constraints: The official label requires Maexeni to be discontinued at least four weeks before and through two weeks after major surgery or prolonged immobilization to mitigate the risk of thromboembolism.

Mechanism of Action

How Maexeni Works

Maexeni exerts its effect by targeting specific signaling components within biological systems that govern overactive physiological responses. Its mechanism initiates at the cellular level by interacting with key sites in the domains involving receptor-mediated signaling. This interaction acts as a modulator, initiating or suppressing specific intracellular signaling sequences.

This molecular adjustment modifies the activity of early regulatory steps, thereby influencing systemic physiological outcomes. Downstream, Maexeni engages mechanisms within complex mechanistic cascades where multiple layers of pathway activation occur, impacting feedback regulation within those pathways. This action leads to subsequent physiological adjustments by limiting the release or activity of specific mediators, resulting in an altered state of regulation within the targeted system.

Dosage and Administration Information

How Maexeni is Used

Maexeni is administered as an oral tablet for long-term, cyclical use as a Combined Oral Contraceptive. The use protocol centers on a precise, daily administration schedule to maintain consistent systemic hormone levels.


Dosing and Administration Schedule

Feature Guideline
Route of Administration Oral (by mouth).
Dosing Schedule One tablet taken daily, without exception. The regimen is cyclic, utilizing either a 28-day or an extended 91-day pack containing active and low-dose/inactive tablets.
Frequency and Timing The tablet must be taken at the same time every day, ensuring the interval between doses does not exceed 24 hours.
Timing with Meals Maexeni may be taken without regard to meals.

Procedural Instructions and Population Use

Standard procedures are established for beginning the first cycle. Initiation can follow either the Day 1 Start (first day of the menstrual period) or the Sunday Start method. For users employing the Sunday Start, a back-up, non-hormonal contraceptive method is required for the first seven days of tablet administration.

Cycle Continuation mandates starting the subsequent pack immediately after the last tablet of the previous pack, without any unscheduled break, regardless of the timing of menstrual bleeding. Procedural guidelines also cover handling missed doses or instances of vomiting or severe diarrhea occurring shortly after active tablet ingestion. The medicine is not indicated for postmenopausal women.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Maexeni

Evidence for use in Chronic Plaque Psoriasis

Research has extensively explored how Maexeni was evaluated in adults with chronic plaque psoriasis, a condition marked by functional limitations and conditions characterized by fluctuating or episodic manifestations. The studies have primarily involved randomized controlled trials, a specific type of research where the outcomes of people receiving Maexeni was compared against those receiving a placebo (an inactive treatment). The trials focused on outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states.

Evidence for use in Psoriatic Arthritis

Maexeni was studied for use in patients diagnosed with psoriatic arthritis, a condition that often involves outcomes related to systemic or functional imbalance and joint discomfort. The research here also involved trials that monitored how joint swelling and pain, as patient-reported outcomes describing perceived discomfort, evolved in the observed populations. The research examined whether Maexeni was associated with patterns related to changes in outcomes reflecting daily functioning or activity level.

Evidence for use in Ankylosing Spondylitis

The use of Maexeni in individuals with active ankylosing spondylitis was observed in trials that monitored outcomes linked to inflammatory or irritative states in the spine. These studies applied in research contexts involving fluctuating or unstable symptoms and measured changes in spinal stiffness and mobility. Research describes patterns related to changes in symptoms, particularly in outcomes related to systemic or functional imbalance within the observed populations.

What is Still Uncertain About Maexeni

Long-term effects are not fully established because the evidence is limited by shorter follow-up durations compared to the expected lifespan of the condition. Evidence quality varies across studies, and findings were mixed for some outcomes. The main evidence gaps include a lack of sufficient data on long-term outcomes and limited comparative evidence against all other available treatment options. Additionally, research provides context but not individual predictions, and the studies so far reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Maexeni (FAQ)

Q: How quickly do people typically start to feel the effects of Maexeni?

Official guidelines state that the body typically requires at least seven days to adjust before the intended contraceptive effect is established. Regulatory guidance specifies that a back-up method for pregnancy prevention is required for the first seven days with certain starting regimens.

Q: Does Maexeni stay in your system for a long time?

Maexeni is designed for daily intake to ensure consistent hormone levels are maintained in the body. Upon discontinuation, official information indicates that the components are quickly metabolized, with the return to fertility generally occurring within one month.

Q: Is Maexeni a strong medicine compared to others in its class?

Maexeni is classified as a Combined Oral Contraceptive (COC) that uses a combination of synthetic hormones for pregnancy prevention. Maexeni is a formulation that contains specific doses of synthetic hormones that are recognized within this class of medicine.

Q: Can Maexeni cause weight gain or weight loss?

Official regulatory data lists 'Weight Increased' as a Common side effect (occurring in 1/100 to < 1/10 users). Official documentation does not typically list weight loss as a documented side effect.

Q: Is it normal to feel tired or dizzy when starting Maexeni?

Fatigue (tiredness) and dizziness are described in product information as common side effects. These effects, if experienced, are often most noticeable during the first few months as the body adjusts.

Q: Can you take Maexeni with vitamins or supplements?

The official product label specifies that certain herbal supplements, such as St John's wort, are known to reduce the effectiveness of Maexeni. Interactions with other vitamins or general supplements are not typically addressed on the product label.

Q: Are there any foods or drinks to avoid while taking Maexeni?

The medicine may be taken without regard to meals. Official interaction lists generally do not prohibit common foods or drinks. The medicine may be taken with food, which is often done to minimize common side effects such as nausea.

Q: Does the official label address the use of Maexeni in individuals with kidney issues?

While severe liver disease is a formal contraindication, official product information describes the use of the medicine with caution in individuals with renal (kidney) impairment. Blood pressure should be closely monitored in these circumstances.

Q: Has Maexeni been studied in children or teenagers?

The medicine is not indicated for use before the start of menstruation (menarche). Regulatory documents state that safety and effectiveness are expected to be similar in postpubertal adolescents (age < 16) and adult users.

Q: Is Maexeni a drug that people need to take long-term?

Maexeni is intended for long-term, daily use by women of childbearing potential to provide consistent pregnancy prevention. It is taken for as long as contraception is desired, assuming no safety concerns or contraindications arise.

Q: What happens if someone misses a dose of Maexeni?

The official label provides detailed instructions for missed doses that depend on the number of pills missed and where they occur in the cycle. Missing a dose increases the chance of pregnancy, and specific procedures outline when a back-up contraceptive method must be used.

Q: Is Maexeni addictive or habit-forming?

No. Maexeni is a hormonal contraceptive and is not classified as a controlled substance by U.S. regulatory agencies.

Q: Can older adults safely use Maexeni?

The medicine is not indicated for use in postmenopausal women. Additionally, use is formally contraindicated for smokers aged 35 or older due to significantly increased cardiovascular risks.

Q: Does Maexeni affect sleep patterns?

Official adverse reaction lists for this medicine do not specifically include sleep disturbances or insomnia as common side effects.

Q: Are there different versions or brands of Maexeni available?

Maexeni is one brand name for the specific combination of the two synthetic hormones, Ethinyl Estradiol and Levonorgestrel. This formulation is widely available worldwide under numerous other brand names and generic versions.

Q: What is the difference between Maexeni and the older treatments for the same condition?

Maexeni is part of a generation of Combined Oral Contraceptives (COCs) which are classified by the specific dose and type of synthetic hormones they contain. Newer formulations generally use lower hormone doses than the original COCs developed decades ago.

Q: Is there a generic version of Maexeni available?

Yes, the active ingredients in Maexeni, Ethinyl Estradiol and Levonorgestrel, are available in many generic and other brand-name formulations worldwide.

Q: Can Maexeni make existing medical conditions worse?

Yes, official warnings indicate the medicine is contraindicated in individuals with uncontrolled high blood pressure or diabetes with vascular complications. Maexeni itself may also cause new onset or worsening of high blood pressure, requiring caution and monitoring.

Q: Does Maexeni interact with alcohol?

Official drug interaction lists do not explicitly prohibit alcohol consumption. However, alcohol may worsen certain common side effects, such as headache or nausea. Long-term heavy alcohol use can also worsen the cardiovascular risk factors associated with hormonal contraceptives.

Q: Can taking Maexeni affect the results of lab tests?

Yes, the estrogen component of the medicine can alter the serum concentrations of certain binding proteins. This may affect the results of some specific laboratory and endocrine function tests.

Q: Are there any long-term effects of taking Maexeni that people should be aware of?

Official documents state that the long-term effects are not fully established due to shorter follow-up durations in studies. However, documented rare long-term risks include Hepatic Neoplasia (liver tumors) and gallbladder disease.

Q: Is it true that Maexeni can cause mood changes?

'Depressed Mood' is listed as a Common adverse reaction in the regulatory documents. The official label notes that caution is advised for individuals who have a history of depression.

Q: Does Maexeni have a boxed warning in its official prescribing information?

While the specific Maexeni oral tablet label may not contain a Boxed Warning, this type of combination product is universally associated with serious warnings concerning the use of the medicine alongside cigarette smoking in females over 35.

Q: What kind of monitoring is usually required when taking Maexeni?

Official guidance advises that blood pressure should be monitored at routine visits. The medicine is required to be stopped if blood pressure rises significantly during use.

Q: Can people with high blood pressure take Maexeni?

Use is formally contraindicated in individuals with uncontrolled high blood pressure. For women with well-controlled high blood pressure, careful monitoring is still required, and the medicine must be stopped if blood pressure rises significantly.

Q: Does the effectiveness of Maexeni change over time?

The intended effectiveness of the medicine in preventing pregnancy is maintained through strict, consistent daily administration. Official safety data indicates that the risk of certain serious side effects, such as VTE (blood clots), is highest during the first year of use and decreases afterward.

Q: What does the research say about stopping Maexeni suddenly?

Official instructions cover the procedure for a missed dose or for stopping before surgery. The discontinuation of the medicine results in a loss of its contraceptive effect, with fertility generally returning quickly to pre-use levels.

Q: Does Maexeni cause problems with vision?

Official warnings identify unexplained loss of vision, double vision, or retinal vascular lesions as signs of a rare, serious event. Regulatory warnings state that if these symptoms occur, the medicine must be discontinued and immediate medical evaluation is required.

Q: Can Maexeni affect fertility?

The medicine is intended to prevent pregnancy while in use. Fertility generally returns to pre-use levels after stopping the medicine, with women typically resuming ovulation and achieving pregnancy soon after discontinuation.

Q: What are the most common reasons patients stop taking Maexeni?

Clinical studies cite common reasons for discontinuation, including a desire to become pregnant, irregular or unexpected bleeding, and specific side effects such as changes in mood or headache.

Q: Is Maexeni known to interact with herbal remedies?

Yes, regulatory documents specifically list the herbal supplement St John’s wort as one of the substances that can increase the metabolism of the hormonal components, potentially diminishing the contraceptive effect.

Q: Does taking Maexeni require any special lifestyle changes?

Yes, official instructions require the medicine to be discontinued at least four weeks before and through two weeks after major surgery or prolonged immobilization. Smoking is also a formal contraindication for females over 35.

Q: What happens to the body when Maexeni starts to work?

Maexeni's combination of synthetic hormones modulates specific signaling pathways within the body. This action limits the activity of key mediators to achieve its intended function of regulating the reproductive cycle to prevent pregnancy.

Q: Is Maexeni a controlled substance?

No, Maexeni is a prescription-only hormonal contraceptive and is not designated as a controlled substance by U.S. regulatory agencies.

Q: How does the scientific evidence for Maexeni compare to similar drugs?

Official research reviews indicate that while the studies support Maexeni's use for its indicated purpose, there is often limited comparative evidence available against all other treatment options in the class.

Q: Can Maexeni affect mental sharpness or focus?

While 'Depressed Mood' is a reported side effect, official adverse reaction lists do not specifically include loss of mental sharpness or focus as a common side effect.

Q: Are allergic reactions to Maexeni common?

Regulatory documents list serious adverse reactions but do not typically classify severe allergic reactions (anaphylaxis) by frequency. Regulatory information notes that if signs of a severe allergic reaction occur, immediate medical evaluation is required.

Q: Does taking Maexeni increase the risk of infections?

Regulatory product information notes that vaginitis (inflammation of the vagina) and vaginal candidiasis (a type of yeast infection) are listed as documented adverse reactions in some patients.

Q: Is there a specific patient profile for whom Maexeni is most appropriate?

Maexeni is indicated for use by females of reproductive potential to prevent pregnancy. It is most appropriate for individuals who do not have any specific absolute contraindications, such as a history of blood clots, smoking over age 35, or certain cancers.

Q: Do the side effects of Maexeni usually go away over time?

Some common side effects, such as nausea, are often temporary and most noticeable during the first few months of use. This occurs as the body adjusts to the hormonal components.

How should Maexeni be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation defines the necessary conditions for storing Maexeni tablets to maintain their labeled 3-year stability. The medicine must be stored at an ambient temperature that does not exceed 30°C.

Storage Scope Regulatory Requirement
Temperature Limit Do not store above 30°C.
Shelf-Life 3 years.
Child Protection Must be kept out of the sight and reach of children.
Disposal Rule Dispose of unused product or waste material in accordance with local requirements.

The drug is supplied in sealed blisters and should be maintained in this packaging. The requirement to store below 30 C is directly connected to ensuring the 3-year product stability. Disposal of this product must strictly follow the appropriate local regulations for discarding medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maexeni found in:

A-Z Index: